Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study

Makoto Ueno(Kanagawa Prefectural Hospital Organization), Junji Furuse(Kanagawa Prefectural Hospital Organization), Satoshi Kobayashi(Kanagawa Cancer Center), Suguru Asada(Ono Pharmaceutical (Japan)), Izumi Ohno(National Cancer Center Hospital East), Naohiro Okano(Kyorin University), Takuji Okusaka(National Cancer Centre Japan), Shunsuke Kondo(University of Hawaiʻi at Mānoa), Keisuke Kimura(Ono Pharmaceutical (Japan)), Chigusa Morizane(Tokyo National Hospital), Yoshinobu Namba(Ono Pharmaceutical (Japan)), Masafumi Ikeda(National Cancer Center Hospital East)
˜The œLancet. Gastroenterology & hepatology
May 17, 2019
10.1016/s2468-1253(19)30086-x
Cited by 331

Related Papers

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1k
The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective
|The Oncologist|2010|977
Trans-ancestry mutational landscape of hepatocellular carcinoma genomes
|Nature Genetics|2014|780